Notably, all GLP-1 RA drugs have demonstrated an efficient prevention of rapid postprandial spikes in blood glucose levels [9,10,11,12,13] and a significant reduction in visceral obesity, a key player in cardiovascular diseases and breast, prostate, ovary, and liver cancers [14,15]. Here, GCG is linked to cardiovascular disorder.